Rabeprazole + clopidogrel vs omeprazole + clopidogrel vs clopidogrel alone in volunteers with different CYP2C19 genotypes

Trial Profile

Rabeprazole + clopidogrel vs omeprazole + clopidogrel vs clopidogrel alone in volunteers with different CYP2C19 genotypes

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Nov 2011

At a glance

  • Drugs Clopidogrel; Omeprazole; Rabeprazole
  • Indications Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Duodenal ulcer; Dyspepsia; Embolism and thrombosis; Gastric ulcer; Gastro-oesophageal reflux; Helicobacter infections; Ischaemic heart disorders; Myocardial infarction; Peptic ulcer; Peripheral arterial occlusive disorders; Reflux oesophagitis; Stroke; Unstable angina pectoris; Zollinger-Ellison syndrome
  • Focus Pharmacodynamics; Pharmacogenomic
  • Most Recent Events

    • 17 Nov 2011 New trial record
    • 02 Nov 2011 Results presented at the 76th Annual Scientific Meeting of the American College of Gastroenterology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top